The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of nivolumab (ONO-4538/BMS-936558) in patients with esophageal cancer: Preliminary report of overall survival.
 
Takashi Kojima
Research Funding - Merck Serono (Inst); Ono Pharmaceutical (Inst)
 
Hiroki Hara
Honoraria - Ono Pharmaceutical
 
Kensei Yamaguchi
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Merck Serono; Takeda
 
Shuichi Hironaka
Honoraria - Lilly; Novartis; Ono Pharmaceutical
Speakers' Bureau - Yakult Honsha
Expert Testimony - Lilly
 
Satoru Iwasa
Honoraria - Chugai Pharma; Takeda
Speakers' Bureau - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda
Research Funding - AbbVie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst); Yakult Pharmaceutical (Inst)
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Lilly; Nippon Kayaku; Pfizer; Sanofi; Taiho Pharmaceutical
Speakers' Bureau - Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kyowa Hakko Kirin; Lilly; MSD; Nippon Kayaku
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst); Yakult Pharmaceutical (Inst)
 
Takahiro Tsushima
Honoraria - Ono Pharmaceutical
 
Hirofumi Yasui
No Relationships to Disclose
 
Takashi Ura
Honoraria - Bayer Yakuhin; Chugai Pharma; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Kei Muro
Speakers' Bureau - Taiho Pharmaceutical
 
Taroh Satoh
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Ono Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Chugai Pharma; Merck Serono
Research Funding - Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Yakult Honsha (Inst)
 
Yuichiro Doki
Honoraria - Ono Pharmaceutical
Research Funding - Ethicon (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Honoraria - Bayer Yakuhin
 
Yasuo Hamamoto
Honoraria - Ono Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Yuko Kitagawa
Honoraria - Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)